🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT02673996
Recruiting Observational

POTS Adrenergic Ab (CIHR Aims #1&2)

NCT02673996 · tracked via the Priya Life Science Canada tracker
Phase
Observational
Started
2016-01
Last updated
2026-05-05

Condition(s) studied

Postural Tachycardia Syndrome

Investigational drug(s) / intervention(s)

Phenylephrine →Isoproterenol →

Phenylephrine: incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg

Isoproterenol: incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm

Study summary

Objective: In this pilot study, we will test the hypothesis that patients with POTS (age 18-60 years) will have a higher percentage of functional antibodies to adrenergic receptors compared with control subjects without POTS.

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients who have been previously diagnosed with POTS * Control subjects (patients not diagnosed with POTS) * Age between 18 - 60 years * Males and Females (Give that \>80% of POTS patients are female, we will attempt to enroll a similar percentage of female control subjects) * Able and willing to provide consent Exclusion Criteria: * Smokers * Overt cause for postural tachycardia, i.e., acute dehydration * Significant cardiovascular, pulmonary, hepatic, or hematological disease by history or prior testing * Highly trained athletes * Subjects with somatization or severe anxiety symptoms will be excluded * Use of drospirenone (a spironolactone analogue) containing oral contraceptive agent * Hypertension defined as supine resting BP\>145/95 mmHg off medications or needing antihypertensive medication * Other factors which in the investigator's opinion would prevent the participant from completing the protocol, including poor compliance during previous studies or an unpredictable schedule * Unable to give informed consent

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Calgary Calgary Alberta Recruiting

More University of Calgary trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02673996 on ClinicalTrials.gov ↗ ← All trials in Canada